While Jiankui He gets all the attention, don’t overlook the giant step that Editas is taking today on the CRISPR front
As health officials the world over — and especially in China — breathe fire over Jiankui He’s apparently credible claims that he skated clear of regulators and genetically altered the embryos of two newborns to guard them against HIV, Editas $EDIT today is celebrating a critical milestone in the long, hard journey to launching its first human trial with major implications for the CRISPR field.
This article is for premium subscribers only
Upgrade to a premium subscription plan for unlimited access, and join our community of key biopharma players.